Lipid based particulate formulations for the delivery of antigen

Immunology and Cell Biology

Volumn 83, Issue 2, 2005, Pages 97-105

  Copland, Melissa J ^a   Rades, Thomas ^a   Davies, Nigel M ^a   Baird, Margaret A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Adjuvant; Antigen delivery; Lipid; Particulate

Indexed keywords

ACYLGLYCEROL; ADJUVANT; ALUMINUM HYDROXIDE; AMPHOPHILE; BUFFER; CHOLIC ACID; DODECYL SULFATE SODIUM; FREUND ADJUVANT; GAP JUNCTION PROTEIN; GLYCEROL BEHENATE; HEMAGGLUTININ; INFLUENZA VACCINE; ISCOM; LIPID A; LIPOSOME; LIQUID PARAFFIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NIOSOME; PHOSPHATIDYLCHOLINE; POLYSORBATE 80; SOLID LIPID NANOPARTICLE; SORBITAN TRIOLEATE; SQUALENE; SURFACTANT; TRANSFERSOME; UNCLASSIFIED DRUG; VIROSOME; VIRUS SIALIDASE;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; BIOCOMPATIBILITY; CHEMICAL COMPOSITION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; EMULSION; ENDOCYTOSIS; HERPES SIMPLEX VIRUS 1; HYDROPHILICITY; HYDROPHOBICITY; IMMUNE RESPONSE; INFLUENZA VIRUS; LANGERHANS CELL; MEASLES VIRUS; MICELLIZATION; PARTICLE SIZE; PH; PHASE TRANSITION; PHOSPHOLIPID BILAYER; REVIEW; SOLUBILITY; TH1 CELL; TRANS GOLGI NETWORK; TRANSMISSION ELECTRON MICROSCOPY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MICROSCOPY, ELECTRON; VIROSOMES;

EID: 16344384382     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1711.2005.01315.x     Document Type: Review

References (70)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
2. Kennedy RT et al. Meeting Report, 2nd meeting on novel adjuvants currently in/close to human clinical testing. World Health Organization - Organization Mondaile la Sante Foundation Merieux, Annecy, France; 5-7 June 2000. Vaccine 2002; 20: 2155-63.
3. Schijns V. Mechanisms of vaccine adjuvant activity: initiation and regulation of immune responses by vaccine adjuvants. Vaccine 2003; 21: 829-31.
4. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993; 11: 293-306.
5. Zinkernagel RM. On cross-priming of MHC class I-specific CTL: rule or exception? Eur. J. Immunol. 2002; 32: 2385-92.
6. Singh M, O'Hagan D. Recent advances in vaccine adjuvants. Pharm. Res. 2002; 19: 715-28.
7. Small DM. Surface and bulk interactions of lipids and water with a classification of biologically active lipids based on these interactions. Federation Proc. 1970; 29: 1320-26.
8. Olbrich C, Muller RH, Tabatt K, Kayser O, Schulze C, Schade R. Stable biocompatible adjuvants - a new type of adjuvant based on solid lipid nanoparticles: a study on cytotoxicity, compatibility and efficacy in chicken. Altern. Lab. Anim. 2002; 30: 443-58.
9. Olbrich C, Bakowsky U, Lehr CM, Muller RH, Kneuer C. Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J. Control. Release 2001; 77: 345-55.
10. Muller R, Radtke M, Wissing S. Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 2002; 242: 121-8.
11. Dingler A, Gohla S. Production of solid lipid nanoparticles (SLN): scaling up feasibilities. J. Microencapsul. 2002; 19: 11-16.
12. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterisation and applications. Adv. Drug Deliv. Rev. 2001; 47: 165-96.
13. Muller R, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 2000; 50: 161-77.
14. Olbrich C et al. Solid lipid nanoparticles (SLN) as vaccine adjuvant - study in sheep with a Mycoplasma bovis antigen and stability testing. International Symposium on Controlled Release of Bioactive Materials; 2000, Paris, France. Paris: The Controlled Release Society, 2000.
15. Olbrich C, Kayser O, Muller R. Stability and biocompatibility optimised vaccine adjuvant (SBA) - Based on solid lipid nanoparticles (SLN). International Symposium on Controlled Release of Bioactive Matter; 2001, San Diego, CA, USA. San Diego: The Controlled Release Society, 2001.
16. Schöler N, Hahn H, Muller RH, Liesenfeld O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int. J. Pharm. 2002; 231: 167-76.
17. Crommelin D, Schreier H. Liposomes. In: Kreuter 3 (ed.) Collodal Drug Delivery Systems. New York: Marcel Dekker, 1994; 73-190.
18. New R. Liposomes: a practical approach. In: Richwood D, Hames B (eds). The Practical Approach Series. Oxford: IRL Press at Oxford University Print, 1990.
19. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol. Today 1990; 11: 89-97.
20. Parnham MJ, Wetzig H. Toxicity screening of liposomes. Chem. Phys. Lipids 1993; 64: 263-74.
21. Richards R, Rao M, Wassef NM, Glenn GM, Rothwell SW, Alving CR. Liposomes containg lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS, S Malaria antigen. Infect. Immun. 1998; 66: 2859-65.
22. Serre K, Machy P, Grivel JC et al. Effecient presentation of multivalent antigens targeted to various cell surface moleules of dendritic cells and surface Ig of antigen-specific B cells. J. Immunol. 1998; 161: 6059-67.
23. Machy P, Serre K, Lesserman L. Class I-restricted presentation of exogenous antigen acquired by Fc gamma receptor-mediated endocytosis is regulated in dendritic cells. Eur. J. Immunol. 2000; 30: 848-57.
24. Copland MJ, Baird MA, Rades T et al. Liposomal delivery of antigen to dendritic cells. Vaccine 2003; 21: 883-90.
25. Drummond DC, Zignani M, Leroux J. Current status of pH-sensitive liposomes in drug delivery. Prog. Lipid Res. 2000; 39: 409-60.
26. Zhou F, Huang L. Delivery of protein antigen to the major histocompatibility complex class I-restricted antigen presentation pathway. J. Drug Target. 1995; 3: 91-109.
27. Reddy R, Zhou F, Huang L, Carbone F, Bevan M, Rouse BT. pH sensitive liposomes provide an efficient means of sensitizing target cells to class I restricted CTL recognition of a soluble protein. J. Immunol. Methods 1991; 141: 157-63.
28. du Plessis J, Ramachandran C, Weiner N, Müller DG. The influence of lipid composition and lamellarity of liposomes on the physical stability of liposomes upon storage. Int. J. Pharm. 1996; 127: 273-8.
29. Hernandez-Cselles T, Villalain J, Gomez-Fernandez JC. Stability of liposomes on long term storage. J. Pharm. Pharmacol. 1990; 42: 397-400.
30. Davis S, Illum L. Colloidal carriers and drug targeting. Acta Pharm. Technol. 1986; 32: 4-9.
31. Kersten GF, Crommelin DJ. Liposomes and ISCOMS as vaccine formulations. Biochim. Biophys. Acta 1995; 1241: 117-38.
32. Phillips NC, Gagne L, Ivanoff N, Riveau G. Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens. Vaccine 1996; 14: 898-904.
33. Phillips NC, Emili A. Immunogenicity of immunoliposomes. Immunol. Lett. 1991; 30: 291-6.
34. Allen TM, Austin GA, Chonn A, Lin L, Lee KC. Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size. Biochim. Biophys. Acta 1991; 1061: 56-64.
35. Rao M, Alving C. Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. Adv. Drug Deliv. Rev. 2000; 41: 171-88.
36. Gerard CM, Baudson N, Kraemer K et al. Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine 2001; 19: 2583-9.
37. Cevc G, Gebauer D, Stieber J, Schatzlein A, Blume G. Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim. Biophys. Acta 1998; 1368: 201-15.
38. Cevc G, Schaltzlein A, Richardsen H. Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. Biochim. Biophys. Acta 2002; 1564: 21-30.
39. Cevc G. Lipid suspensions on the skin. Permeation enhancement, vesicle penentration and transdermal drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 1996; 13: 257-388.
40. Paul A, Cevc G, Bachhawat B. Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradefonnable drug carriers, transfersomes. Vaccine 1998; 16: 188-95.
41. Walter E, Dreher D, Kok M et al. Hydrophilic poly (DL-lactide-co- glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells. J. Control Release 2001; 76: 149-68.
42. Conacher M, Alexander J, Brewer JM. Niosomes as immunological adjuvants. In: Uchegbu I (ed.) Synthetic Surfactant Vesicles. Singapore: International Publishers Distrubtors, 2000; 185-205.
43. Rentel CO, Bouwstra JA, Naisbett B, Junginger HE. Niosomes as a novel peroral vaccine delivery system. Int. J. Pharm. 1999; 186: 161-7.
44. Murdan S, Gregoriadis G, Florence AT. Sorbitan monostearate/ polysorbate 20 organogels containing niosomes: a delivery vehicle for antigens? Eur. J. Pharm. Sci. 1999; 8: 177-86.
45. Ambrosch F, Wiedermann G, Jonas S et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997; 15: 1209-13.
46. Gluck R, Walti E. Biophysical validation of Epaxal Berna, a hepatitis A vaccine adjuvanted with immunopotentiating reconstituted influenza virosomes (IR1V). Dev. Biol. 2000; 103: 189-97.
47. Bungener L, Serre K, Bijl L, Leserman L, Wilschut J, Daemen T, Machy P. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 2002; 20: 2287-95.
48. Moser C, Metcalfe IC, Viret JF. Virosomal adjuvanted antigen delivery systems. Expert Rev. Vaccines 2003; 2: 189-96.
49. Martin A. Physical chemical principles in the pharmaceutical sciences. In: Martin A, Bustamante P, Chun AHC (eds.) Physical Pharmacy. Philadelphia: Lea & Febiger, 1983.
50. Engberts J, Kevelam J. Formation and stability of micelles and vesicles. Curr. Opin. Colloid Interface Sci. 1996; 1: 779-89.
51. Villacres-Eriksson M. Antigen presentation by naive macrophages, dendritic cells and B cells to primed T lymphocytes and their cytokine production following exposure to immunostimulating complexes. Clin. Exp. Immunol. 1995; 102: 46-52.
52. Alvring C. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 2002; 20: S56-S64.
53. Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol. 1999; 17: 1075-81.
54. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19: 2673-80.
55. Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001; 19: 2666-72.
56. Gupta RK, Siber GR. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 1995; 13: 1263-76.
57. Muderhwa JM, Matyas GR, Spitler LE, Alving CR. Oil-in-water liposomal emulsions: Characterisation and potential use in vaccine delivery. J. Pharm. Sci. 1999; 88: 1332-9.
58. Bomford R, Stapleton M, Winsor S et al. Adjuvanticity and ISCOM formation by structurally diverse saponins. Vaccine 1992; 10: 572-7.
59. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984; 308: 457-60.
60. Coulter A, Wong TY, Drane D, Bates J, Macfarlan R, Cox J. Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulation complexes (Iscoms) and oil-in-water vaccines. Vaccine 1997; 16: 1243-53.
61. Sjölander A, Drane D, Maraskovsky E et al. Immune responses to ISCOM formulations in animal and primate models. Vaccine 2001; 19: 2661-5.
62. Villacres MC, Behboudi S, Nikkila T, Lovgren-Bengtsson K, Morein B. Internalization of iscom-borne antigens and presentation under MHC class I or class II restriction. Cell. Immunol. 1998; 185: 30-38.
63. Tarpey I, Stacey SN, McIndoe A, Davies DH. Priming in vivo and quantification in vitro of class I MHC-restricted cytotoxic T cells to human papilloma virus type II early proteins (E6 and E7) using immunostimulating complexes (ISCOMs). Vaccine 1996; 14: 230-36.
64. Behboudi S, Morein B, Ronnberg B. Isolation and quantification of Quillaja saponaria Molina saponins and lipids in iscom-matrix and iscoms. Vaccine 1995; 13: 1690-96.
65. Rimmelzwaan GF, Nieuwkoop N, Brandenburg A et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 2000; 19: 1180-87.
66. Reid G. Soluble proteins incorporate into ISCOMs after covalent attachment of fatty acid. Vaccine 1992; 10: 597-602.
67. Barr IG, Sjolander A, Cox JC. ISCOMs and other saponin based adjuvants. Adv. Drug Deliv. Rev. 1998; 32: 247-71.
68. Lazorova L, Artursson P, Engstrom A, Sjolander A. Transport of an influenza virus vaccine formulation (iscom) in Caco-2 cells. Am. J. Physiol. 1996; 270: G554-64.
69. Mowat A, Maloy K, Donachie A. Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. Immunology 1993; 80: 527-34.
70. Small DM. A classification of biologic lipids based upon their interaction in aqueous systems. J. Am. Oil Chemists Soc. 1968; 45: 108-19.